Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas

Trial Profile

Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carmustine
  • Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 26 Mar 2012 Planned end date changed from 1 Dec 2009 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top